NOVARTIS AG
CIK 1114448 · last filed 2020-07-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.65B
Companies
14
Total Filings
46
Lifetime Open-Market Net
$7.62M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Poseida Therapeutics, Inc. (PSTX) Delisted | 10%+ Owner | 5,908,089 | $9.50 | $56.13M | $0 | 1 | 2020-07-16 |
| Akouos, Inc. (AKUS) Delisted | 856,262 | $13.29 | $11.38M | $4.25M | 1 | 2020-07-02 | |
| Galera Therapeutics, Inc. (GRTX) Delisted | 10%+ Owner | 3,489,559 | $0.14 | $506.0K | -$729.4K | 2 | 2020-06-12 |
| Whitehawk Therapeutics, Inc. (ARPO) Delisted | 10%+ Owner | 5,193,108 | $33.00 | $171.37M | -$695.9K | 2 | 2019-04-05 |
| Rein Therapeutics, Inc. (ALRN) Delisted | 10%+ Owner | 2,434,778 | $2.11 | $5.14M | $7.47M | 6 | 2018-08-16 |
| ALT | 10%+ Owner | 5,597,357 | $2.61 | $14.61M | $0 | 4 | 2018-06-15 |
| NTLA | 10%+ Owner | 4,129,903 | $12.11 | $50.01M | -$45.74M | 3 | 2017-12-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 2,307,877 | — | — | $781.6K | 4 | 2017-06-12 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | 10%+ Owner | 2,310,924 | $12.01 | $27.75M | $6.00M | 1 | 2016-04-12 |
| KINETA, INC./DE (PTI) Delisted | 10%+ Owner | 1,498,791 | — | — | $6.00M | 1 | 2016-02-17 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | 10%+ Owner | 4,524,885 | — | — | $5.56M | 5 | 2015-07-15 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | 33,185,191 | — | — | $10.23M | 9 | 2011-04-13 | |
| Adhera Therapeutics, Inc. (MRNAD) Delisted | 10%+ Owner | 2,804,670 | — | — | -$619.8K | 3 | 2011-01-25 |
| ALNY | 10%+ Owner | 5,602,898 | $282.85 | $1.58B | $15.11M | 3 | 2010-04-26 |
Recent Filings · Page 2 of 5
46 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-07-25 | Rein Therapeutics, Inc. (ALRN) Delisted | Sell (S) | −62,600 | -$265.9K | EDGAR |
| 2018-06-15 | ALT | Other (J) | +1,441,756 | $0 | EDGAR |
| 2018-05-17 | ALT | Other (J) | +2,084,862 | $0 | EDGAR |
| 2018-03-19 | ALT | Other (J) | +523,938 | $0 | EDGAR |
| 2017-12-14 | NTLA | Sell (S) | −3,046,000 | -$55.74M | EDGAR |
| 2017-11-16 | ALT | Other (J) | +364,524 | $0 | EDGAR |
| 2017-07-05 | Rein Therapeutics, Inc. (ALRN) Delisted | Mixed | +5,088,364 | $8.00M | EDGAR |
| 2017-06-12 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Sell (S) | −1,400 | -$30.8K | EDGAR |
| 2017-06-06 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Sell (S) | −39,294 | -$918.9K | EDGAR |
| 2017-05-22 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Sell (S) | −18,038 | -$459.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.